Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

848

Participants

Timeline

Start Date

January 1, 2007

Primary Completion Date

October 28, 2008

Study Completion Date

November 19, 2008

Conditions

Chemotherapy-Induced Nausea and Vomiting

Interventions

DRUG

aprepitant

aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.

DRUG

Comparator: ondansetron

Ondansetron 8 mg capsule Three day treatment period.

DRUG

Comparator: dexamethasone

dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.

DRUG

Comparator: fosaprepitant dimeglumine

fosaprepitant dimeglumine 115 mg

DRUG

Comparator; Placebo (unspecified)

dexamethasone 12mg Pbo tablets.

DRUG

Comparator; Placebo (unspecified)

Aprepitant 80 mg \& 125 mg Pbo capsules.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00337727 - Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) | Biotech Hunter | Biotech Hunter